NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease
Standard treatment for advanced non-small cell lung cancer (NSCLC) historically consisted of systemic cytotoxic chemotherapy until the early 2000s, when precision medicine led to a revolutionary change in the therapeutic scenario. The identification of oncogenic driver mutations in EGFR, ALK and ROS...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/12/6748 |
| _version_ | 1797486384569647104 |
|---|---|
| author | Anna Michelotti Marco de Scordilli Elisa Bertoli Elisa De Carlo Alessandro Del Conte Alessandra Bearz |
| author_facet | Anna Michelotti Marco de Scordilli Elisa Bertoli Elisa De Carlo Alessandro Del Conte Alessandra Bearz |
| author_sort | Anna Michelotti |
| collection | DOAJ |
| description | Standard treatment for advanced non-small cell lung cancer (NSCLC) historically consisted of systemic cytotoxic chemotherapy until the early 2000s, when precision medicine led to a revolutionary change in the therapeutic scenario. The identification of oncogenic driver mutations in EGFR, ALK and ROS1 rearrangements identified a subset of patients who largely benefit from targeted agents. However, since the proportion of patients with druggable alterations represents a minority, the discovery of new potential driver mutations is still an urgent clinical need. We provide a comprehensive review of the emerging molecular targets in NSCLC and their applications in the advanced setting. |
| first_indexed | 2024-03-09T23:33:26Z |
| format | Article |
| id | doaj.art-afd60f58b9064900ba9d5b8f5756ea06 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T23:33:26Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-afd60f58b9064900ba9d5b8f5756ea062023-11-23T17:06:08ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-06-012312674810.3390/ijms23126748NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced DiseaseAnna Michelotti0Marco de Scordilli1Elisa Bertoli2Elisa De Carlo3Alessandro Del Conte4Alessandra Bearz5Department of Medicine (DAME), University of Udine, 33100 Udine, ItalyDepartment of Medicine (DAME), University of Udine, 33100 Udine, ItalyDepartment of Medicine (DAME), University of Udine, 33100 Udine, ItalyCentro di Riferimento Oncologico di Aviano (CRO) IRCCS, Department of Medical Oncology, 33081 Aviano, ItalyCentro di Riferimento Oncologico di Aviano (CRO) IRCCS, Department of Medical Oncology, 33081 Aviano, ItalyCentro di Riferimento Oncologico di Aviano (CRO) IRCCS, Department of Medical Oncology, 33081 Aviano, ItalyStandard treatment for advanced non-small cell lung cancer (NSCLC) historically consisted of systemic cytotoxic chemotherapy until the early 2000s, when precision medicine led to a revolutionary change in the therapeutic scenario. The identification of oncogenic driver mutations in EGFR, ALK and ROS1 rearrangements identified a subset of patients who largely benefit from targeted agents. However, since the proportion of patients with druggable alterations represents a minority, the discovery of new potential driver mutations is still an urgent clinical need. We provide a comprehensive review of the emerging molecular targets in NSCLC and their applications in the advanced setting.https://www.mdpi.com/1422-0067/23/12/6748NSCLC<i>MET</i><i>RET</i><i>NTRK</i><i>KRAS</i><i>HER2</i> |
| spellingShingle | Anna Michelotti Marco de Scordilli Elisa Bertoli Elisa De Carlo Alessandro Del Conte Alessandra Bearz NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease International Journal of Molecular Sciences NSCLC <i>MET</i> <i>RET</i> <i>NTRK</i> <i>KRAS</i> <i>HER2</i> |
| title | NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease |
| title_full | NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease |
| title_fullStr | NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease |
| title_full_unstemmed | NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease |
| title_short | NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease |
| title_sort | nsclc as the paradigm of precision medicine at its finest the rise of new druggable molecular targets for advanced disease |
| topic | NSCLC <i>MET</i> <i>RET</i> <i>NTRK</i> <i>KRAS</i> <i>HER2</i> |
| url | https://www.mdpi.com/1422-0067/23/12/6748 |
| work_keys_str_mv | AT annamichelotti nsclcastheparadigmofprecisionmedicineatitsfinesttheriseofnewdruggablemoleculartargetsforadvanceddisease AT marcodescordilli nsclcastheparadigmofprecisionmedicineatitsfinesttheriseofnewdruggablemoleculartargetsforadvanceddisease AT elisabertoli nsclcastheparadigmofprecisionmedicineatitsfinesttheriseofnewdruggablemoleculartargetsforadvanceddisease AT elisadecarlo nsclcastheparadigmofprecisionmedicineatitsfinesttheriseofnewdruggablemoleculartargetsforadvanceddisease AT alessandrodelconte nsclcastheparadigmofprecisionmedicineatitsfinesttheriseofnewdruggablemoleculartargetsforadvanceddisease AT alessandrabearz nsclcastheparadigmofprecisionmedicineatitsfinesttheriseofnewdruggablemoleculartargetsforadvanceddisease |